Ottobock is a global MedTech company with a strategic investment arm focused on human mobility, prosthetics, neuro-orthotics, and assistive technologies. Unlike a traditional venture fund, it invests with strong strategic intent, often in Series A and B rounds where its manufacturing, clinical, and distribution infrastructure can provide differentiated value. It is one of the strongest strategic corporates in adjacent neurotechnology markets.

Its neurotech-related investments include ONWARD Medical and Phantom Neuro, reflecting interest in spinal stimulation, neural interfaces, and technologies that restore function. Ottobock’s core strength is the ability to connect portfolio companies to patient care networks, device manufacturing, and rehabilitation channels. For founders working in assistive neurotechnology, that kind of ecosystem access can be unusually powerful.

Ottobock invests globally, with particularly strong presence in Europe and North America. For neurotech companies in prosthetics, rehabilitation, spinal cord stimulation, and related human-performance or restoration categories, it is a highly relevant strategic investor. It is especially valuable when distribution and clinical integration matter as much as financing.